Liposomal-lupane system as alternative chemotherapy against cutaneous leishmaniasis: Macrophage as target cell

Experimental Parasitology

Volumn 135, Issue 2, 2013, Pages 337-343

  Barros, Neuza B ^a   Migliaccio, Vanessa ^a   Facundo, Valdir A ^b   Ciancaglini, Pietro ^c   Stábeli, Rodrigo G ^a   Nicolete, Roberto ^a   Silva Jardim, Izaltina ^a,d  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b UNIVERSIDADE FEDERAL DE RONDÔNIA   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d DEPARTAMENTO DE CIÊNCIAS BIOLÓGICAS   (Brazil)

Author keywords

Leishmania amazonensis; Liposomes; Lupane; Macrophages

Indexed keywords

ANTILEISHMANIAL AGENT; INTERLEUKIN 10; INTERLEUKIN 12; LIPOSOME; LUPANE; PENTAMIDINE; TRITERPENE DERIVATIVE; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBRETUM; COMBRETUM LEPROSUM; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PARASITE SURVIVAL; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROMASTIGOTE; SKIN LEISHMANIASIS;

LEISHMANIA AMAZONENSIS; LIPOSOMES; LUPANE; MACROPHAGES;

ANIMALS; ANTIPROTOZOAL AGENTS; COMBRETUM; DISEASE MODELS, ANIMAL; INTERLEUKIN-10; INTERLEUKIN-12; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; LIPOSOMES; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED BALB C; PENTAMIDINE; PLANT EXTRACTS; TRITERPENES;

EID: 84883342268     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2013.07.022     Document Type: Article

References (24)

1. Alonso M.J., Losa C., Calvo P., Vila-Jato J.L. Approaches to improve the association of amikacin sulphate to poly(alkylcyanoarylate) nanoparticles. Int. J. Pharm. 1991, 68:69-76.
2. Bailey M.S., Lockwood D.N. Cutaneous leishmaniasis. Clin. Dermatol. (Philadelphia) 2007, 25(2):203-211.
3. Batista C.M., Carvalho C.M.B., Magalhães N.S.S. Lipossomas e suas aplicações terapeutas: Estado da Arte. Revista Brasileira de Ciências Farmacêuticas 2007, 43(2):167-179.
4. Dzubak P., Hajduch M., Vydra D. Pharmacological activities of natural triterpenoids and their therapeutic implications. Nat. Prod. Rep. 2006, 23:341-394.
5. Facundo V.A., Andrade C.H.S., Silveira E.R. Triterpenes and flavonoids from C. leprosum. Phytochemistry 1993, 32:411-415.
6. Giaimis J., Lombard Y., Makaya-Kumba M. A new and simple method for studying the binding and ingestion steps in the phagocytosis of yeasts. J. Immunol. Methods 1992, 154(2):185-193.
7. Izumi E., Morello L.G., Ueda-Nakamura T. Antileishmanial activity of parthenolide, a sesquiterpene lactone isolated from Tanacetum parthenium. Exp. Parasitol. 2008, 118:324-330.
8. Kalyankar T.M., Khan M., Rangari N.T. Novel possibilities of development and therapeutic applications of Liposomes. J. Pharm. Res. 2010, 3(8):1880-1884.
9. Kedzierski L., Sakthianandeswaren A., Curtis J.M. Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr. Med. Chem. 2009, 16(5):599-614.
10. Lima E.B., Motta J.O.C., Porto C. Tratamento da Leishmaniose Tegumentar Americana. An. Bras. Dermatol. 2007, 82(2):114-124.
11. Mosqueira V.C.F., Legrand P., Pinto-Alphandary H. Poly(d,l-lactide) nanocapsules prepared by a solvent displacement process: influence of the composition on physicochemical and structural properties. J. Pharm. Sci. 2000, 89:614-626.
12. Murray H.W., Lu C.M., Mauze S. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun. 2002, 70(11):6284-6293.
13. Nicoletti S., Seifert K., Gilbert I.H. N-(2-hydroxypropyl) methacrylamide-amphotericin B (HPMA-AmB) copolymer conjugates as antileishmanial agents. Int. J. Antimicrob. Agents 2009, 33(5):441-448.
14. Piscopo T.V., Mallia A.C. Leishmaniasis. Postgrad. Med. J. 2006, 82(972):649-657.
15. Ranzani-Paiva M.J.T., Santos A.A., Dias D.C. Hematological and phagocytic response of fat snook, Centropomus parallelus, reared in net cages, before and after inoculation with Saccharomyces cerevisiae. Bioikos 2008, 22(1):29-35.
16. Rath S., Trivelin L.A., ImbrunitoI T.R. Antimoniais empregados no tratamento da leishmaniose. Química Nova 2003, 26(4):550-555.
17. Saha S., Mondal S., Banerjee A. Immune responses in kala-azar. Indian J. Med. Res. 2006, 123(3):245-266.
18. Silveira F.T., Lainson R., Corbett C.E.P. Further observations on clinical, histopathological, and immunological features of borderline disseminated cutaneous leishmaniasis caused by Leishmania (Leishmania) amazonensis. Mem. Inst. Oswaldo Cruz 2005, 100(5):525-534.
19. Teles C.B.G., Moreira L.S., Silva A.A.E. Activity of the lupane isolated from Combretum leprosum against Leishmania amazonensis promastigotes. J. Braz. Chem. Soc. 2011, 22(5):936-942.
20. Tempone A.G., Mortara R.A., Andrade H.F. Therapeutic evaluation of free and liposome-loaded furazolidone in experimental visceral leishmaniasis. J. Antimicrob. Chemother. 2004, 60:526-534.
21. Tempone A.G., Perez D., Rath S. Targeting Leishmania (L.) chagasi amastigotes through macrophage scavenger receptors: the use of drugs entrapped in liposomes containing phosphatidylserine. J. Antimicrob. Chemother. 2005, 54:60-68.
22. Trinchieri G., Pflanz S., Kastelein R.A. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003, 19(5):641-644.
23. Xu R., Fazio G.C., Matsuda S.P.T. On the origins of triterpenoid skeletal diversity. Phytochemistry 2004, 65(3):261-291.
24. Yotsumoto S., Kakiuchi T., Aramali Y. Enhancement of IFN-gamma production for Th1 cell therapy using negatively charged liposomes containing phosphatidylserine. Vaccine 2007, 25(29):5256-5262.